⚠ IMPORTANT DISCLAIMER

This product is sold for research purposes only. It is not intended for human consumption, nor is it intended to diagnose, treat, cure, or prevent any disease.

Reconstitute with bacteriostatic (BAC) water for laboratory research preparation.

Tesamorelin 5mg Research Peptide (RUO)

£75.00

Tesamorelin 5mg is supplied by Vitalis Peptide Research strictly for laboratory research use only.
Product information is provided to support legitimate scientific and analytical research by qualified professionals.

In Stock

-
+
Add to Wishlist
Add to Wishlist
Category:

Description

Overview
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog supplied
in lyophilised form for laboratory research use only. In preclinical literature,
Tesamorelin has been examined for its interaction with the GHRH receptor and
downstream cAMP/PKA signalling in pituitary axis model systems.

Research Context
– Investigated in models assessing GH/IGF‑1 axis dynamics and hypothalamic–pituitary
signalling.
– Used in controlled in vitro and in vivo experimental designs with protocol‑specific
outcomes.
– Biochemical focus includes receptor binding profiles and second‑messenger pathways.

Format and Documentation
– Lyophilised peptide; nominal content: 5 mg per vial
– Certificate of Analysis (COA) provided for each lot
– Storage guidance for research settings on label/COA

Compliance
For laboratory research use only (RUO). Not for human or veterinary use, diagnostic
or therapeutic applications.

Form: Lyophilised powder
Intended use: Laboratory research use only
Documentation: Certificate of Analysis where applicable
Dispatch: Fast UK fulfilment
Storage:
– Powder: -20°C 3 years ; 4°C 2 years ; 15°C 3 month
– In solvent: -80°C 6 months ; -2°C 1 month ; 10°C 1 week

Product disclaimer
This product is supplied strictly for laboratory research use only. Not for human or veterinary

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin 5mg Research Peptide (RUO)”

Your email address will not be published. Required fields are marked *